Status: One Wales interim decision | |
Using the agreed starting and stopping criteria dostarlimab (Jemperli®) can be made available within NHS Wales for the first-line treatment of locally advanced stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer. This recommendation applies only in circumstances where the approved commercial arrangement price is applied. The risks and benefits of the off-label use of dostarlimab (Jemperli®) for this indication should be clearly stated and discussed with the patient to allow informed consent. Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed. This advice will be reviewed after 12 months or earlier if new evidence becomes available. |
|
Medicine details |
|
Medicine name | dostarlimab (Jemperli®) |
Formulation | 500 mg concentrate for solution for infusion |
Reference number | OW26 |
Indication | First-line treatment of locally advanced stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer |
Company | GlaxoSmithKline UK |
BNF chapter | Malignant disease & immunosuppression |
Submission type | One Wales |
Status | One Wales interim decision |
Advice number | OW26 |
AWMSG meeting date | 11/07/2023 |
Ratification by Welsh Government | 03/08/2023 |
Date of issue | 03/08/2023 |